CMPX
Income statement / Annual
Last year (2023), Compass Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Compass Therapeutics, Inc.'s net income was -$42.49 M.
See Compass Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
03/31/2020 |
03/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.89 M |
$1.90 M |
$1.62 M |
$2.40 M |
$2.12 M |
$1.92 M |
| Gross Profit |
-$1.89 M |
-$1.90 M |
-$1.62 M |
-$2.40 M |
-$2.12 M |
-$1.92 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$37.42 M
|
$30.00 M
|
$20.34 M
|
$14.90 M
|
$22.45 M
|
$27.10 M
|
| General & Administrative
Expenses |
$12.24 M
|
$11.66 M
|
$10.93 M
|
$12.91 M
|
$11.60 M
|
$11.22 M
|
| Selling & Marketing
Expenses |
$11.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.05 M
|
$11.66 M
|
$10.93 M
|
$12.91 M
|
$11.60 M
|
$11.22 M
|
| Other Expenses |
$0.00 |
$0.00 |
$50.62 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$48.47 M |
$41.66 M |
$31.26 M |
$27.81 M |
$34.05 M |
$38.31 M |
| Cost And Expenses |
$50.36 M |
$41.66 M |
$31.26 M |
$27.81 M |
$34.05 M |
$38.31 M |
| Interest Income |
$0.00 |
$2.36 M |
$29,000.00 |
$88,000.00 |
$743,000.00 |
$663,000.00 |
| Interest Expense |
$0.00 |
$2.36 M |
$370,000.00 |
$908,000.00 |
$1.23 M |
$767,000.00 |
| Depreciation &
Amortization |
$1.89 M
|
$1.90 M
|
$1.62 M
|
$2.40 M
|
$2.12 M
|
$1.92 M
|
| EBITDA |
-$48.47 M
|
-$37.39 M
|
-$29.61 M
|
-$25.32 M
|
-$31.19 M
|
-$35.73 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$7.87 M
|
$2.43 M
|
-$299,000.00
|
-$1.66 M
|
-$601,000.00
|
$233,000.00
|
| Income Before Tax |
-$42.49 M |
-$39.23 M |
-$82.18 M |
-$29.47 M |
-$34.65 M |
-$38.18 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.43 M |
$370,000.00 |
$32,000.00 |
$91,000.00 |
$103,000.00 |
| Net Income |
-$42.49 M |
-$36.80 M |
-$82.55 M |
-$29.50 M |
-$34.74 M |
-$38.29 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.33 |
-0.35 |
-1.31 |
-0.96 |
-0.67 |
-0.73 |
| EPS Diluted |
-0.33 |
-0.35 |
-1.31 |
-0.96 |
-0.67 |
-0.73 |
| Weighted Average Shares
Out |
$127.03 M
|
$105.19 M
|
$62.87 M
|
$30.78 M
|
$52.11 M
|
$52.11 M
|
| Weighted Average Shares
Out Diluted |
$127.03 M
|
$105.19 M
|
$62.87 M
|
$30.78 M
|
$52.11 M
|
$52.11 M
|
| Link |
|
|
|
|
|
|
